DOMAIN Therapeutics

DOMAIN Therapeutics

Verified
Committed to improve patients’ life and to support physicians by delivering innovative immunotherapies to fight cancer

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues5m5m8m5m9m--
% growth150 %-60 %(38 %)80 %--
EBITDA<1m<1m<1m(5m)(4m)--
% EBITDA margin10 %(4 %)(1 %)(100 %)(44 %)--

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
€3mSeries A
€16mSeries B
€8.2mSeries C
N/A€2.1mSeries D
€2mEarly VC
N/A$230kGrant
*
€3.5mLate VC
*
N/A€6mDebt
*
$42mSeries A
Total Funding$80.5m

Recent News about DOMAIN Therapeutics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by DOMAIN Therapeutics

Edit
Prestwick Chemical Inc.
ACQUISITION by DOMAIN Therapeutics Mar 2020
Neurofit SAS
ACQUISITION by DOMAIN Therapeutics Mar 2020